Literature DB >> 18551193

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

Alan G Ramsay1, Amy J Johnson, Abigail M Lee, Güllü Gorgün, Rifca Le Dieu, William Blum, John C Byrd, John G Gribben.   

Abstract

Cancer is associated with immune deficiency, but the biologic basis of this is poorly defined. Here we demonstrate that impaired actin polymerization results in CD4+ and CD8+ T cells from patients with chronic lymphocytic leukemia (CLL) exhibiting defective immunological synapse formation with APCs. Although this synapse dysfunction was in part a result of the CLL cells having poor APC function, defective actin polymerization was also identified in T cells from patients with CLL. We further demonstrate that, following contact with CLL cells, defects in immune synapse formation were induced in healthy allogeneic T cells. This required direct contact and was inhibited by blocking adhesion molecules on CLL B cells. In T cells from patients with CLL and in T cells from healthy individuals that had been in contact with CLL cells, recruitment of key regulatory proteins to the immune synapse was inhibited. Treatment of autologous T cells and CLL cells with the immunomodulating drug lenalidomide resulted in improved synapse formation. These results define what we believe to be a novel immune dysfunction in T cells from patients with CLL that has implications for both autologous and allogeneic immunotherapy approaches and identifies repair of immune synapse defects as an essential step in improving cancer immunotherapy approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551193      PMCID: PMC2423865          DOI: 10.1172/JCI35017

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies.

Authors:  A Trojan; J L Schultze; M Witzens; R H Vonderheide; M Ladetto; J W Donovan; J G Gribben
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse.

Authors:  Regina Tavano; Rita Lucia Contento; Sonia Jimenez Baranda; Marzia Soligo; Loretta Tuosto; Santos Manes; Antonella Viola
Journal:  Nat Cell Biol       Date:  2006-10-22       Impact factor: 28.824

3.  Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.

Authors:  John G Gribben; David Zahrieh; Katherine Stephans; Lini Bartlett-Pandite; Edwin P Alyea; David C Fisher; Arnold S Freedman; Peter Mauch; Robert Schlossman; Lecia V Sequist; Robert J Soiffer; Blossom Marshall; Donna Neuberg; Jerome Ritz; Lee M Nadler
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

4.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.

Authors:  David H Chang; Nancy Liu; Virginia Klimek; Hani Hassoun; Amitabha Mazumder; Stephen D Nimer; Sundar Jagannath; Madhav V Dhodapkar
Journal:  Blood       Date:  2006-03-28       Impact factor: 22.113

5.  Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.

Authors:  U Klein; Y Tu; G A Stolovitzky; M Mattioli; G Cattoretti; H Husson; A Freedman; G Inghirami; L Cro; L Baldini; A Neri; A Califano; R Dalla-Favera
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

6.  Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues.

Authors:  S Harig; M Witzens; A M Krackhardt; A Trojan; P Barrett; R Broderick; A J Zauls; J G Gribben
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

7.  Wasp recruitment to the T cell:APC contact site occurs independently of Cdc42 activation.

Authors:  J L Cannon; C M Labno; G Bosco; A Seth; M H McGavin; K A Siminovitch; M K Rosen; J K Burkhardt
Journal:  Immunity       Date:  2001-08       Impact factor: 31.745

8.  Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse.

Authors:  Maria Isabel Thoulouze; Nathalie Sol-Foulon; Fabien Blanchet; Alice Dautry-Varsat; Olivier Schwartz; Andrés Alcover
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

9.  Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Authors:  Amy J Johnson; David M Lucas; Natarajan Muthusamy; Lisa L Smith; Ryan B Edwards; Michael D De Lay; Carlo M Croce; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

10.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

View more
  244 in total

Review 1.  The immunological synapse.

Authors:  Michael L Dustin
Journal:  Cancer Immunol Res       Date:  2014-11       Impact factor: 11.151

2.  Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Stefania Fiorcari; Silvia Martinelli; Jenny Bulgarelli; Valentina Audrito; Patrizia Zucchini; Elisabetta Colaci; Leonardo Potenza; Franco Narni; Mario Luppi; Silvia Deaglio; Roberto Marasca; Rossana Maffei
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

3.  Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.

Authors:  Januario E Castro; Johanna Melo-Cardenas; Mauricio Urquiza; Juan S Barajas-Gamboa; Ramin S Pakbaz; Thomas J Kipps
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

Review 4.  Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.

Authors:  John G Gribben; Chitra Hosing; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

5.  Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Authors:  Jason A Dubovsky; Daniel Wang; John J Powers; Emmanuel Berchmans; Matthew A Smith; Kenneth L Wright; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2010-09-22       Impact factor: 3.156

Review 6.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

7.  Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

Authors:  Alan G Ramsay; Rachel Evans; Shahryar Kiaii; Lena Svensson; Nancy Hogg; John G Gribben
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

8.  Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Authors:  Aaron P Rapoport; Nicole A Aqui; Edward A Stadtmauer; Dan T Vogl; Yin Yan Xu; Michael Kalos; Ling Cai; Hong-Bin Fang; Brendan M Weiss; Ashraf Badros; Saul Yanovich; Gorgun Akpek; Patricia Tsao; Alan Cross; Dean Mann; Sunita Philip; Naseem Kerr; Andrea Brennan; Zhaohui Zheng; Kathleen Ruehle; Todd Milliron; Scott E Strome; Andres M Salazar; Bruce L Levine; Carl H June
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

9.  "Cell biology meets physiology: functional organization of vertebrate plasma membranes"--the immunological synapse.

Authors:  Silvia Curado; Sudha Kumari; Michael L Dustin
Journal:  Curr Top Membr       Date:  2013       Impact factor: 3.049

Review 10.  Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.

Authors:  Alexander M Lesokhin; Susan Bal; Ashraf Z Badros
Journal:  Cancer Immunol Res       Date:  2019-08       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.